Navigation Links
Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death

physicians and patients immediately so that treatment decisions may be based on all the available evidence."

Richard Nesto, MD, Chairman of the Department of Cardiovascular Medicine at the Lahey Clinic Medical Center, said these new findings provide important information for physicians caring for diabetic patients. "Despite its limitations, the recent meta-analysis in the New England Journal of Medicine raised important questions about the cardiac safety of rosiglitazone. These questions can only be answered with better evidence from clinical trials. This interim analysis of RECORD, a randomized prospective clinical trial, helps to establish the overall cardiac safety profile of the drug," said Dr. Nesto, who is an author of the American Heart Association and American Diabetes Association consensus statement on the use of thiazolidinediones in diabetic patients with heart disease. "Additional clinical trials are underway to specifically address this issue, but the data from RECORD should be reassuring for physicians who need effective drugs to lower blood sugar levels -- the main cornerstone of treatment for diabetic patients."

The RECORD study's robust design and breadth make it uniquely suited to answer questions about cardiovascular risk with Avandia.

First, the study was designed to include a wide range of Type 2 diabetes patients, including those with and without existing cardiovascular disease, making it highly representative of real-world diabetes patients. Second, patients in RECORD were managed such that blood sugar remained within current guidelines, thereby eliminating a variable that may affect results, as inadequate blood sugar control is itself associated with cardiovascular events. Third, although an open-label design, each cardiovascular event was verified by an independent panel of physicians who did not know which medicines the patients were taking.

Under these rigorous standards, the interim analysis shows that the inci
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

Post Your Comments:
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 /PRNewswire/ -... Prabhavathi Fernandes, president and chief execut...t Annual Health Care Conference at 8:50 a.m. EST, ...New York City. Dr. Fernandes will provide an over...cal programs for the treatment of drug-resistant p...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Repor...eport is available in its catalogue: ,, Intran...is http://www.reportlinker.com/p0164267/Intranas... ,, The US intranasal drug delivery market is ...s from the delivery of conventional local therapeu...
(Date:11/25/2009)... , FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNe... (Nasdaq: HTWR ; ASX: HIN), a leading innovator a...tory support technologies revolutionizing the trea...hat it is scheduled to make an investor presentati...nference at 8:00 am EST on Wednesday, December 2, ...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 1New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 2New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 3News briefs from the October issue of Chest 58908 1News briefs from the October issue of Chest 58908 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 1HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 3
...ain, Sept. 25 Five-year follow-up overall,surviva...ncer Trial) study,show that oral chemotherapy Xelo...t standard treatment - intravenous bolus 5-FU/LV (...tment of Dukes, C colon cancer. These,data were pr...ce (ECCO) in,Barcelona, Spain. Results show five-...
... Hearing Loss Program With Novel SiRNA Approaches ...g Candidate, AHLI-11, For The, Prevention Of Che...ge, FREMONT, Calif., Sept. 24 Quark Pharmaceutic...ny focused on discovering and,developing novel RNA...that,it has signed a collaboration agreement with ...
Other Medicine Technology:Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 2Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 3Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 4Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 2Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 3
(Date:11/27/2009)...ch firm Replikins Ltd. today issued its latest bio... It shows that the lethality of the virus has drop...us,s current outbreak in the spring of 2009 to res...1). The H1N1 infectivity count, however, remains i...) November 27, 2009 -- Biotech firm Replikins Ltd....
(Date:11/27/2009)...v. 27 Preventing diseas...rtunately every year, new vaccines are being added...nes boost immunity for the same period of time? An...ded to keep immunity strong? ,, In this month...n Academy of Pediatrics, Michael Pichichero MD, Di...
(Date:11/27/2009)...are Holdings has announced that it has become a na... the largest nonprofit organizations dedicated to ... Delray Beach, FL (Vocus) ...B: XCHO), a company specializing in the marketing ...ducts, has announced today that is has become a na...
(Date:11/27/2009)...TTLE, Nov. 27 Allrecipes.com , ...nksgiving traffic numbers, with more than 2.8 mill...g a clear picture of what was served on the bigges...ng meal in 2009 weighed in at 2,225 calories per s...t. According to the Allrecipes site, Sweet Potato...
(Date:11/27/2009)...alist manufacturers who use medical load cells at ... dollars by bringing in technology partner Flintec...f pro-active medical manufacturers are calling in ...their projects, ensuring that progress will not be...tially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...h suggests that gene therapy is a safe treatment m... at risk for amputation because of poor// circulat...ase I clinical trial, almost half the patients rec...rienced complete healing of those ulcers in the sa...
... finds that single-slice magnetic resonance imagin...intra-abdominal fat//. Excessive intra-abdomin...loping heart disease, diabetes and other illnesses...in and around the abdominal organs may actually be...
... patients have cholesterol higher than national gu...ented the stroke from happening//, according to a ...entific journal of the American Academy of Neurolo...mmended by national guidelines. TIA happens when b...
...die each year from lung cancer than from breast, o...ho smoke are more likely than men to develop lung ...eater risk than their male counterparts. Screening...still curable. If you’re considering having a scre...
...have long known the molecular mechanisms behind mo... example//, is made possible in part by rhodopsin,... light. It is involved in turning photons into ele...as remained a mystery. “For a long time, we...
...tuffed the pungent bulbs down their throats in hop...eases-don’t do so anymore//, say researchers. ...Medicine have come out with a myth basher-garlic h...nal Archives of Internal Medicine, lead author Dr....
Other Medicine News:Health News:Gene Therapy Shows Promise as Treatment for Diseased Limbs 2Health News:Gene Therapy Shows Promise as Treatment for Diseased Limbs 3Health News:Single Slice MRI- Handy Tool to Identify Children at Risk 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 3Health News:Garlic-Not So Good Anymore 2
Bores Corneal Fixation Forceps
Moody Curved Fixation Forceps
Green Straight Fixation Forceps
Pierse Type Micro Forceps - Straight
Medicine Products: